Clinical outcomes of immunomodulation therapy in immunocompromised patients with severe Covid-19 and high oxygen requirement
Avigayil Goldstein(Rabin Medical Center), Michal Landes(Tel Aviv University), Jacob Strahilevitz(Hebrew University of Jerusalem), Ronza Najjar‐Debbiny(Carmel Medical Center), Sarah Israel(Hadassah Medical Center), Ronen Ben‐Ami(Tel Aviv University), Meital Elbaz(Tel Aviv University), Tali Shafat(The University of Texas MD Anderson Cancer Center), Ami Neuberger(Technion – Israel Institute of Technology), Amir Shlomai(Tel Aviv University), Jihad Bishara(Tel Aviv University), Yazeed Qassem Darawsha(Rambam Health Care Campus), Daniel Grupel(Ben-Gurion University of the Negev), Ariel Weil(Hebrew University of Jerusalem), Khetam Hussein(Rambam Health Care Campus)
Cited by 4
Related Papers
Global guideline for the diagnosis and management of mucormycosis: an initiative of the European Confederation of Medical Mycology in cooperation with the Mycoses Study Group Education and Research Consortium
|The Lancet Infectious Diseases|2019|1.7k
Fluoroquinolone-modifying enzyme: a new adaptation of a common aminoglycoside acetyltransferase
|Nature Medicine|2005|1k
Plasmid-Mediated Quinolone Resistance: a Multifaceted Threat
|Clinical Microbiology Reviews|2009|930
<i>qnr</i> Prevalence in Ceftazidime-Resistant <i>Enterobacteriaceae</i> Isolates from the United States
|Antimicrobial Agents and Chemotherapy|2006|576
Plasmid-Mediated Quinolone Resistance
|Microbiology Spectrum|2014|469